+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-17Number of Pages: 176

Scleroderma Diagnostics and Therapeutics Market (Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors; Indication - Localized and Systemic; Diagnostic Test Type - Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

According to Transparency Market Research, the global scleroderma diagnostics and therapeutics market was valued at US$1,633.5 mn in 2015 and is projected to expand at a CAGR of 9.7% from 2016 to 2024 to reach US$3,663.7 mn by 2024.

scleroderma diagnostics therapeutics market

 

Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed over 8.0% share of the global scleroderma therapeutics market in 2015, and is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America accounted for a share of nearly 34.0% while Europe held nearly 30% of the global scleroderma therapeutics market in 2015. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting CAGRs of 11.2% and 10.9%, respectively, over the period between 2016 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
        4.1.1. Drug Class Definition
        4.1.2. Industry Developments
4.2. Market Dynamics
        4.2.1. Drivers
        4.2.2. Restraints
        4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014–2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials

Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication 
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
        5.3.1. Localized
        5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments

Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
        6.3.1. Corticosteroids
        6.3.2. Immunosuppressive Agents
        6.3.3. Endothelin receptor antagonists 
        6.3.4. Calcium Channel Blockers
        6.3.5. PDE-5 Inhibitors
        6.3.6. Chelating Agents
        6.3.7. Prostacyclin analogues
        6.3.8. Others 
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments

Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
        7.3.1. North America
        7.3.2. Europe
        7.3.3. Asia Pacific
        7.3.4. Latin America
        7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends

Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication 
        8.3.1. Localized
        8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
        8.4.1. Corticosteroids
        8.4.2. Immunosuppressive Agents
        8.4.3. Endothelin receptor antagonists 
        8.4.4. Calcium Channel Blockers
        8.4.5. PDE-5 Inhibitors
        8.4.6. Chelating Agents
        8.4.7. Prostacyclin analogues
        8.4.8. Others 
8.5. Market Size (US$ Mn) Forecast, by Country
        8.5.1. U.S.
        8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends

Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
        9.3.1. Localized
        9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
        9.4.1. Corticosteroids
        9.4.2. Immunosuppressive Agents
        9.4.3. Endothelin receptor antagonists 
        9.4.4. Calcium Channel Blockers
        9.4.5. PDE-5 Inhibitors
        9.4.6. Chelating Agents
        9.4.7. Prostacyclin analogues
        9.4.8. Others 
9.5. Market Size (US$ Mn) Forecast, by Country
        9.5.1. U.K.
        9.5.2. Germany
        9.5.3. France
        9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015 
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends

Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
        10.3.1. Localized
        10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
        10.4.1. Corticosteroids
        10.4.2. Immunosuppressive Agents
        10.4.3. Endothelin receptor antagonists 
        10.4.4. Calcium Channel Blockers
        10.4.5. PDE-5 Inhibitors
        10.4.6. Chelating Agents
        10.4.7. Prostacyclin analogues
        10.4.8. Others 
10.5. Market Size (US$ Mn) Forecast, by Country
        10.5.1. China
        10.5.2. India
        10.5.3. Japan
        10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2015 
10.7. Market Attractiveness Analysis, by Drug Class, 2015
10.8. Key Trends

Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product 
        11.3.1. Localized
        11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
        11.4.1. Corticosteroids
        11.4.2. Immunosuppressive Agents
        11.4.3. Endothelin receptor antagonists 
        11.4.4. Calcium Channel Blockers
        11.4.5. PDE-5 Inhibitors
        11.4.6. Chelating Agents
        11.4.7. Prostacyclin analogues
        11.4.8. Others 
11.5. Market Size (US$ Mn) Forecast, by Country
        11.5.1. Brazil
        11.5.2. Mexico
        11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2015 
11.7. Market Attractiveness Analysis, by Drug Class, 2015
11.8. Key Trends

Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication 
        12.3.1. Localized
        12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
                12.4.1. Corticosteroids
        2.4.2. Immunosuppressive Agents
        12.4.3. Endothelin receptor antagonists 
        12.4.4. Calcium Channel Blockers
        12.4.5. PDE-5 Inhibitors
        12.4.6. Chelating Agents
        12.4.7. Prostacyclin analogues
        12.4.8. Others 
12.5. Market Size (US$ Mn) Forecast, by Country
        12.5.1. UAE
        12.5.2. South Africa
        12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2015 
12.7. Market Attractiveness Analysis, by Drug Class, 2015
12.8. Key Trends

Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
        13.2.1. Actelion Pharmaceuticals, Inc. 
                  13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.2.1.2. Financial Overview
                  13.2.1.3. Product Portfolio
                  13.2.1.4. SWOT Analysis
                  13.2.1.5. Strategic Overview
        13.2.2. Bayer AG
                  13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.2.2.2. Financial Overview
                  13.2.2.3. Product Portfolio
                  13.2.2.4. SWOT Analysis
                  13.2.2.5. Strategic Overview
        13.2.3. Boehringer Ingelheim
                  13.2.3.1. Company Overview (HQ, business segments, employee strength)
                  13.2.3.2. Product Portfolio
                  13.2.3.3. SWOT Analysis
                  13.2.3.4. Financial Overview
                  13.2.3.5. Strategic Overview
        13.2.4. Corbus Pharmaceutical Holdings, Inc. 
                  13.2.4.1. Company Overview (HQ, business segments, employee strength)
                  13.2.4.2. Product Portfolio
                  13.2.4.3. SWOT Analysis
                  13.2.4.4. Strategic Overview
                  13.2.4.5. Key Developments
        13.2.5. Cumberland Pharmaceuticals Inc.
                  13.2.5.1. Company Overview (HQ, business segments, employee strength)
                  13.2.5.2. Financial Overview
                  13.2.5.3. Product Portfolio
                  13.2.5.4. SWOT Analysis
                  13.2.5.5. Strategic Overview
        13.2.6. Cytori Therapeutics, Inc.
                  13.2.6.1. Company Overview (HQ, business segments, employee strength)
                  13.2.6.2. Product Portfolio
                  13.2.6.3. SWOT Analysis
                  13.2.6.4. Financial Overview
                  13.2.6.5. Strategic Overview
        13.2.7. F. Hoffmann La Roche Ltd. 
                  13.2.7.1. Company Overview (HQ, business segments, employee strength)
                  13.2.7.2. Financial Overview
                  13.2.7.3. Product Portfolio
                  13.2.7.4. SWOT Analysis
                  13.2.7.5. Strategic Overview
        13.2.8. Gilead Sciences, Inc. 
                  13.2.8.1. Company Overview (HQ, business segments, employee strength)
                  13.2.8.2. Financial Overview
                  13.2.8.3. Product Portfolio
                  13.2.8.4. SWOT Analysis
                  13.2.8.5. Strategic Overview
        13.2.9. Merck KGaA
                  13.2.9.1. Company Overview (HQ, business segments, employee strength)
                  13.2.9.2. Product Portfolio
                  13.2.9.3. Financial Overview
                  13.2.9.4.  SWOT Analysis
                  13.2.9.5. Strategic Overview
        13.2.10. Pfizer, Inc.
                  13.2.10.1. Company Overview (HQ, business segments, employee strength)
                  13.2.10.2. Product Portfolio
                  13.2.10.3. Financial Overview
                  13.2.10.4. SWOT Analysis
                  13.2.10.5. Strategic Overview
        13.2.11. Sanofi
                  13.2.11.1. Company Overview (HQ, business segments, employee strength)
                  13.2.11.2. Product Portfolio
                  13.2.11.3. Financial Overview
                  13.2.11.4. SWOT Analysis
                  13.2.11.5. Strategic Overview

List of Figures

Figure 1: Global Scleroderma Therapeutics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 2: Global Scleroderma Diagnostics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 3: Scleroderma Therapeutics Market Value Share by Drug Class (2016)
Figure 4: Scleroderma Therapeutics Market Value Share by Indication (2016)
Figure 5: Scleroderma Therapeutics Market Value Share by Region (2016)
Figure 6: Scleroderma Diagnostics Market Value Share by Test Type (2016)
Figure 7: Global Scleroderma Therapeutics Market Value Share Analysis, by Indication Type, 2016 and 2024
Figure 8: Global Localized Scleroderma Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 9: Global Systemic Scleroderma Market Revenue US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 10: Scleroderma Therapeutics Market Attractiveness Analysis, by Indication Type, 2015
Figure 11: Global Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 12: Global Corticosteroids Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 13: Global Immunosuppressive Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 14: Global Endothelin Receptor Agonists Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 15: Global Calcium Channel Blockers Market Revenue ((US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 16: Global PDE-5 Inhibitors Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 17: Global Chelating Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 18: Global Prostacyclin Analogs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 19: Global Other Scleroderma Drugs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 20: Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: Global Scleroderma Therapeutics Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015
Figure 23: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 24: North America Scleroderma Therapeutics Market Size and Y-o-Y Growth Projections, 2015–2024
Figure 25: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 26: North America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 27: North America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: highlights the estimated and forecast market value share of the drug class segments for 2016 and 2014
Figure 28: North America Scleroderma Therapeutics Market Value Share Analysis, by Country, 2016 and 2024
Figure 29: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 30: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 31: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 32: Europe Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 33: Europe Market Attractiveness Analysis, by Country, 2015
Figure 34: Europe Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 35: Europe Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 37: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 38: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 39: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Asia Pacific Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 41: Asia Pacific Market Attractiveness Analysis, by Country, 2015
Figure 42: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 43: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 44: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 45: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 46: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 47: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 48: Latin America Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 49: Latin America Market Attractiveness Analysis, by Country, 2015
Figure 50: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 51: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 52: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 53: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 54: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 55: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 56: Middle East & Africa Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 57: Middle East & Africa Market Attractiveness Analysis, by Country, 2015
Figure 58: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 59: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 60: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 61: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 62: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 63: Global Skin Biopsy Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024 
Figure 64: Global Imaging Techniques Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 65: Global Prostacyclin Analogues Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 66: Global Electrocardiogram & Echocardiogram Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 67: Global Pulmonary Function Tests Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024 
Figure 68: Global Scleroderma Diagnostics Market Attractiveness Analysis, by Test Type, 2015
Figure 69: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015

List of Tables

Table 1: Overview of active clinical trials for scleroderma
Table 2: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 3: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 4: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 5: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 6: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 7: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 8: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 9: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024s
Table 10: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 12: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 13: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 15: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 16: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 18: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 19: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 20: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 21: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 22: North America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 23: Europe Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 24: Asia Pacific Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 25: Latin America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 26: Middle East & Africa Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024

Global Scleroderma Diagnostics and Therapeutics Market: Overview

Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and “derma,” meaning skin. Thus, scleroderma literally translates to “hard skin.” Scleroderma is a group of diseases that involves the abnormal growth of connective tissue, which supports the skin and internal organs. In some forms of scleroderma, the extent of the abnormality of the disease is limited to hard, tight skin. In certain other forms, however, the predicament is worse, where the impact goes much deeper, affecting blood vessels and internal organs, such as the heart, lungs, and kidneys. Scleroderma has no known cure and is a chronic condition, in which patients are affected for life. Localized scleroderma patients, however, with mild symptoms, often see the skin patches disappear on their own in a few years post-onset.

Global Scleroderma Diagnostics and Therapeutics Market: Scope of the Report

This report on the global scleroderma diagnostics and therapeutics market analyzes the current and future prospects of the market. The markets of diagnostics and therapeutics are independently analyzed as two separate markets within the report. The market for scleroderma therapeutics is segmented based on drug class, indication and region, while the market for scleroderma diagnostics is segmented on the basis of test type and region. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as new drug launches, drugs in the pipeline, industry-institute collaborations in research for finding a pertinent cure, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global scleroderma diagnostics and therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Scleroderma Diagnostics and Therapeutics Market: Segmentation

Based on indication, the global scleroderma diagnostics and therapeutics market has been segmented into localized and systemic scleroderma. Localized scleroderma affects only the skin, and in certain patients, the underlying muscle, however, systemic scleroderma (also known as systemic sclerosis) is much severe and affects the internal organs as well.

The major drug classes for treatment of scleroderma include Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, and Others. The others segment includes the drug classes of analgesics, proton pump inhibitors, prokinetic agents, H2 blockers and ACE inhibitors etc. which are used in symptomatic relief to the patient. Immunosuppressive agents and low dose corticosteroids are the most commonly prescribed agents to treat scleroderma.

Based on test type, the diagnostics market has been segmented into skin biopsy, imaging techniques, blood test, electrocardiogram and echocardiogram, and pulmonary function tests. Diagnosis of the disease is based on physician’s assessment of patients’ medical history and clinical manifestations. In addition, tests and procedures are undertaken to validate the clinical diagnosis and exclude alternative diagnoses, and later for assessment of organ involvement and monitoring of disease progression.

Global Scleroderma Diagnostics and Therapeutics Market: Geographical and Competitive Dynamics

Geographically, the global scleroderma diagnostics and therapeutics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries for the scleroderma therapeutics market These include the U.S., Canada, the U.K., Germany, France,  China, Japan, India, Brazil, Mexico, the UAE, and South Africa. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the radiodermatitis market.

The report also profiles major players in the scleroderma therapeutics and diagnostics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Cumberland Pharmaceuticals Inc, Gilead Sciences, Inc., Pfizer, Inc., and Sanofi.

The global scleroderma therapeutics and diagnostics market has been segmented as follows:

Global Scleroderma Therapeutics Market, by Drug Class

  • Corticosteroids
  • Immunosuppressive Agents 
  • Endothelin Receptor Agonists
  • Calcium Channel Blockers
  • PDE-5 Inhibitors
  • Chelating Agents
  • Prostacyclin Analogues
  • Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)

Global Scleroderma Therapeutics Market, by Indication

  • Localized
  • Systemic

Global Scleroderma Diagnostics Market, by Test Type

  • Skin Biopsy
  • Imaging Techniques
  • Blood Tests
  • Electrocardiogram and Echocardiogram
  • Pulmonary Function Tests

Global Scleroderma Diagnostics and Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • Rest of APAC
  • Europe
    • France
    • Germany
    • U.K.
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top